Full-Time

Veeva RIM Specialist

ImmunityBio

ImmunityBio

501-1,000 employees

Develops immunotherapies for cancer and infections

Compensation Overview

$50.48 - $55.53/hr

+ Discretionary Bonus + Equity Award

Summit, NJ, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Veeva
Requirements
  • Bachelor’s Degree in life sciences or technical discipline with 5+ years of regulatory operations experience in the biotechnology or pharmaceutical industry required; or High School diploma with 9+ years’ experience required.
  • Hands on experience with Veeva RIM and Veeva Vault required.
Responsibilities
  • Create and maintain electronic project folders for projects.
  • Execute the upload, tracking, life cycle maintenance of regulatory submissions, including INDs, BLAs, CTAs, for US and ex-US regions within Veeva RIM.
  • Maintain Veeva RIM by uploading all submissions, Health Authority correspondence, etc.
  • Track all regulatory meetings, questions, information requests, and responses ensuring proper linking within Veeva RIM.
  • Upload and manage Word and source documents in Veeva Vault to support collaboration, version control, and document updates.
  • Ensure regulatory documents received via email, secure links, or external portals in addition to gateway submissions are captured and filed appropriately.
  • Assist in responding to internal audits, health authority inspections, and regulatory inquiries related to RIM documentation.
  • Ensure that all working files, forms, sign-out sheets, and archives are organized and maintained in accordance with SOPs and Health Authority requirements.
  • Configure Vault objects, lifecycles, workflows, document types, and metadata to support business processes.
  • Provide technical and functional support for users including, but not limited to, access to Veeva RIM
  • Assist in system validation, upgrades, and testing, ensuring compliance with GxP and regulatory standards.
  • Partner with regulatory affairs, IT, and clinical teams to translate business requirements into technical solutions.
  • Assist in training Regulatory Documentation Specialists, ensuring that all SOPs are followed, and all questions are answered; Continue to provide support and assist in questions after the training is completed.
  • Act as a key operational contact for Regulatory Affairs regarding Veeva RIM.
  • Provide day-to-day support to system users.
  • Collaborate with other Regulatory Documentation Specialists regarding upgrades to existing software programs, new software programs, or removing software programs that are no longer needed.
  • Performs ad-hoc and cross-functional duties and/or projects, as assigned, to support business needs and provide developmental opportunities.
Desired Qualifications
  • Familiarity with global regulatory submissions and health authority correspondence strongly preferred.

ImmunityBio develops immunotherapies to treat cancer and infectious diseases. It uses natural killer (NK) cell–based therapies and viral vector vaccines to boost the immune system and enable immune cells to attack tumors or infections. The company generates revenue from product sales and licensing agreements, and it focuses on therapies for hard-to-treat cancers and infectious diseases through research, development, and commercialization. Its goal is to outsmart diseases by leveraging the body's natural defenses to give patients more treatment options.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Culver City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 Anktiva sales surge 168% to $44M with approvals in 33 countries.
  • 2026 revenue forecast rises 63% to $230M driven by 92% annual growth.
  • QUILT 2.005 trial fully enrolled supports 2026 sBLA for BCG-naïve NMIBC.

What critics are saying

  • FDA March 24, 2026 warning letter halts misleading Anktiva promotions and sales.
  • Securities lawsuits over Soon-Shiong's claims drain $381M cash by May 26, 2026.
  • Glioblastoma trial failures block Anktiva expansion, slashing 2026 revenue growth.

What makes ImmunityBio unique

  • Anktiva supercharges BCG by amplifying immune response in BCG-unresponsive papillary NMIBC.
  • NCCN 2026 guidelines grant Category 2A recommendation for Anktiva plus BCG in papillary-only NMIBC.
  • QUILT-3.032 cohort B shows 58% 12-month DFS and 92% cystectomy-free at one year.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ImmunityBio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Discounts

Wellness Program

Mental Health Support

Performance Bonus

Pet Insurance

529 Education Savings Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Apr 14th, 2026
ImmunityBio reports $44.2M Q1 revenue from ANKTIVA expansion across 33 countries

ImmunityBio has reported preliminary Q1 2026 net product revenue of approximately $44.2 million, driven by uptake of its drug ANKTIVA and broader approvals. The company's shares currently trade at $7.60, having surged 276% year-to-date, though they fell 9.42% over the past month. Despite recent momentum, the stock has posted a 54% loss over five years, reflecting uneven performance tied to ANKTIVA revenue progress and ongoing regulatory and legal challenges. The most popular analyst narrative values ImmunityBio at $13.50 per share, suggesting 43.7% upside. This valuation assumes aggressive growth from ANKTIVA's expansion into 33 countries, including the US, EU and Saudi Arabia, alongside commercial partnerships. However, this outlook depends on regulatory support, expanded indications beyond bladder cancer, and strong market uptake.

My Malone Telegram
Apr 12th, 2026
IBRX investors have opportunity to lead ImmunityBio, Inc. securities fraud lawsuit first filed by the Rosen Law Firm.

IBRX investors have opportunity to lead ImmunityBio, Inc. securities fraud lawsuit first filed by the Rosen Law Firm. * 2 hrs ago PR Newswire NEW YORK, April 11, 2026 NEW YORK, April 11, 2026 /PRNewswire/ - Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Business Insider
Apr 10th, 2026
Berger Montague PC investigating claims on behalf of ImmunityBio, Inc. (IBRX) investors after class action filing.

Berger Montague PC investigating claims on behalf of ImmunityBio, Inc. (IBRX) investors after class action filing. Apr. 10, 2026, 08:41 AM Philadelphia, Pennsylvania-(Newsfile Corp. - April 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026 (the "Class Period"). Headquartered in San Diego, Calif., ImmunityBio is a clinical-stage biopharmaceutical company developing cancer immunotherapies and vaccines, including the Anktiva platform. According to the Complaint, throughout the Class Period, defendants made materially false and misleading statements about the capabilities of Anktiva. Specifically, the Complaint alleges that during an appearance on a podcast, Chief Scientific and Medical Officer Patrick Soon-Shiong claimed that Anktiva can cure and even prevent all cancer. When the true details entered the market, ImmunityBio's stock declined by $1.98 per share, more than 21%, to close at $7.42 per share on March 24, 2026. If you are an ImmunityBio investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger Montague Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. Andrew Abramowitz Berger Montague (215) 875-3015 [email protected] Caitlin Adorni Berger Montague (267) 764-4865 [email protected] Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Sponsored Financial Content

The Associated Press
Apr 9th, 2026
ImmunityBio Q1 revenue surges 168% to $44M with $381M cash on hand

ImmunityBio has reported preliminary net product revenue of $44.2 million for the quarter ending 31 March 2026, representing a 168% increase over the same period in 2025 and a 15% sequential increase from the previous quarter. The commercial-stage biotechnology company's product ANKTIVA has driven consistent quarterly revenue growth since its commercial launch. The company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities. ANKTIVA is now approved or authorised across five regulatory jurisdictions representing approximately 34 countries. ImmunityBio's pivotal BCG-naïve CIS trial is fully enrolled, with a supplemental biologics licence application submission on track for 2026. The company reported full-year 2025 net product revenue of $113 million, a 700% increase over 2024.

Yahoo Finance
Apr 7th, 2026
ImmunityBio faces FDA warning over misleading ANKTIVA claims, sparking class action suits

ImmunityBio has come under FDA scrutiny after the Office of Prescription Drug Promotion issued a warning letter in late March 2026 over allegedly false or misleading promotional claims for its drug ANKTIVA. The company pulled a cancer-focused podcast and confirmed a related television advert never aired, whilst committing to tighter compliance controls. The regulatory action has triggered multiple securities class action filings alleging investors were misled by the same promotional statements. The development raises questions about management credibility as the company pursues label expansion efforts and potential capital raises. Despite the controversy, an independent committee found ImmunityBio's QUILT-2.005 trial in bladder cancer is adequately powered and fully enrolled, with a supplemental biologics licence application planned for late 2026. The company's narrative projects $1.2 billion revenue by 2029, requiring 118.9% yearly growth.